This article is more than 5 years old. Information may no longer be current.
Outcomes improved in sickle cell patients treated with cementless hip implants
Researchers of this study found the mid-term results of total hip arthroplasty improved in patients with sickle cell anemia who underwent the procedure with cementless prostheses.
“We believe that the outcomes of total hip arthroplasty improved in sickle cell patients with optimized medical management and the use of cementless prosthetic devices,” the authors wrote in their study abstract.
The researchers compared 32 patients with sickle cell disease with a cohort of 87 non-sickle cell osteonecrosis patients. The sickle cell patients had an average age of 37 years and were followed up for an average of 7.5 years. The non-sickle cell patients had an average age of 43 years and were followed for 7 years. The investigators compared the groups for implant survivorship, Harris Hip and SF-36 health questionnaire scores, complication rates and radiographic findings. They discovered no significant differences between the groups for any of the outcome measures.
Disclosure: Issa has no relevant financial disclosures.